Table 3.
Clinical outcomes in 14 patients with long-COVID after 20 days of treatment with H1/H2 receptor blockers and in 13 untreated patients with long-COVID.
| At baseline | 20 days after | |||||
|---|---|---|---|---|---|---|
| Treated patients (n = 14) | Untreated patients (n = 13) | p-Value | Treated patients (n = 14) | Untreated patients (n = 13) | p-Value | |
| Long-COVID (%) | 100 | 100 | 1.0000 | 71 | 100 | 0.0977 |
| Unchanged fatigue (%) | 100 | 100 | 1.0000 | 21 | 85 | 0.0018 |
| Unchanged brain fog (%) | 93 | 85 | 0.5955 | 43 | 70 | 0.2518 |
| Increased HR (%) | 93 | 92 | 1.0000 | 29 | 85 | 0.0063 |
| Abdominal disorders (%) | 79 | 77 | 1.0000 | 14 | 62 | 0.0183 |
HR, heart rate.